BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Best Quest for new employment Site for You to Track down Amazing open doors - 2Vote In favor of Your Number one Savvy Beds
- 3Warming winters lead to more nitrate pollution in the drinking water near farms
- 4Record-breaking flu hospitalizations in New York in a single week: Health officials
- 5Building an Individual Brand: Illustrations from Powerhouses
- Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- 21 Things You Ought to Never Tell Your Childless Companion
- 20-year-old who threatened German train attack remanded in custody
- Aspect Biosystems receives funding for cellular medicine project
- When faith comes under fire: How Iran’s repression of religious minorities has increased
- Europe pledges over €15bn for clean energy for Africa
- Which Espresso Do You Like Best? Vote
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- Germany and trade unions kick off tough public-sector wage talks
